Tirgi atviegloti: Novo Nordisk atsauc savu pied\u0101v\u0101jumu Metsera ieg\u0101dei<\/p>\n
Glob\u0101lie kapit\u0101la tirgi uz\u0146\u0113ma zi\u0146as par Pfizer pan\u0101kumiem c\u012b\u0146\u0101 par pretsvaru z\u0101\u013cu ra\u017eot\u0101ju Metsera ar jauktu reakciju. Lai gan Metsera akciju v\u0113rt\u012bba piedz\u012bvoja kritumu, Novo Nordisk akciju tirgus noska\u0146ojums uzlaboj\u0101s p\u0113c inform\u0101cijas par vi\u0146u izst\u0101\u0161anos no sacens\u012bbas par \u0161o v\u0113rt\u012bgo uz\u0146\u0113mumu.<\/p>\n
Investori, atz\u012bstot d\u0101\u0146u farm\u0101cijas giganta strat\u0113\u0123iski gudro l\u0113mumu, izr\u0101d\u012bja savu piekri\u0161anu, d\u0101v\u0101jot Novo Nordisk akciju v\u0113rt\u012bbas nelielu k\u0101pumu. Tirgus \u0161o atteik\u0161anos interpret\u0113ja k\u0101 pr\u0101t\u012bgu soli, lai izvair\u012btos no p\u0101rmaksas intens\u012bv\u0101 izsoles proces\u0101. \u0160\u0101ds l\u0113mums \u013cauj uz\u0146\u0113mumam saglab\u0101t savu sp\u0113c\u012bgo naudas poz\u012bciju un pilnv\u0113rt\u012bgi koncentr\u0113ties uz savu eso\u0161o un topo\u0161o z\u0101\u013cu kl\u0101stu, kas v\u0113rsts uz aptauko\u0161anos un diab\u0113ta \u0101rst\u0113\u0161anu. \u0160\u012b piesardz\u012bbas pieeja tika uztverta k\u0101 apliecin\u0101jums Novo Nordisk ilgtermi\u0146a izaugsmes perspekt\u012bv\u0101m, nepak\u013caujoties riskiem, kas saist\u012bti ar d\u0101rgiem uz\u0146\u0113mumu ieguld\u012bjumiem.<\/p>\n
Ofici\u0101lais pazi\u0146ojums un dar\u012bjuma deta\u013cas<\/p>\n
Sav\u0101 ofici\u0101laj\u0101 pazi\u0146ojum\u0101 Metsera apstiprin\u0101ja vieno\u0161anos par apvieno\u0161anos ar Pfizer. Saska\u0146\u0101 ar dar\u012bjuma nosac\u012bjumiem Pfizer ieg\u016bs Metsera par summu l\u012bdz 86,25 ASV dol\u0101riem (74,34 eiro) par akciju, no kuriem 65,60 ASV dol\u0101ri (56,5 eiro) tiks samaks\u0101ti skaidr\u0101 naud\u0101. Metsera direktoru padome atzinusi, ka pied\u0101v\u0101jums ir vislabv\u0113l\u0101kais akcion\u0101riem gan v\u0113rt\u012bbas, gan dar\u012bjuma pabeig\u0161anas garantijas zi\u0146\u0101.<\/p>\n
\nPazi\u0146ojum\u0101 Metsera nor\u0101d\u012bja: \u201e\u0145emot v\u0113r\u0101 nesen\u0101s apst\u0101k\u013cus, tostarp sa\u0146emto zvanu no ASV Feder\u0101l\u0101s tirdzniec\u012bbas komisijas par potenci\u0101lajiem riskiem, kas saist\u012bti ar ierosin\u0101t\u0101s Novo Nordisk strukt\u016bras \u012bsteno\u0161anu saska\u0146\u0101 ar ASV pretmonopolu likumiem, Metsera direktoru padome ir t\u0101l\u0101k noteikusi, ka Novo Nordisk pied\u0101v\u0101tais dar\u012bjums rada nepie\u0146emjami augstus juridiskus un regulat\u012bvus riskus Metsera un t\u0101s akcion\u0101riem, sal\u012bdzinot ar ierosin\u0101to apvieno\u0161anos ar Pfizer, ieskaitot riskus, ka s\u0101kotn\u0113j\u0101 dividendes var nekad netikt izmaks\u0101ta vai v\u0113l\u0101k var tikt apstr\u012bd\u0113ta vai atsaukta. Metsera joproj\u0101m ir ap\u0146\u0113musies \u012bstenot apvieno\u0161anos ar Pfizer, kas, Metsera ieskat\u0101, nodro\u0161in\u0101s t\u016bl\u012bt\u0113ju un iev\u0113rojamu v\u0113rt\u012bbu Metsera akcion\u0101riem.\u201d<\/p>\n<\/blockquote>\n
Pfizer savuk\u0101rt pauda gandar\u012bjumu par dar\u012bjumu, piebilstot, ka tas nodro\u0161in\u0101s \u201et\u016bl\u012bt\u0113ju un noteiktu v\u0113rt\u012bbu Metsera akcion\u0101riem\u201d.<\/p>\n
Tirgus dinamika un konkurence farm\u0101cijas nozar\u0113<\/p>\n
Tikm\u0113r Eirop\u0101 nov\u0113rojams Ozempic cenu kritums vis\u0101 kontinent\u0101. Tas skaidrojams ar Novo Nordisk centieniem saglab\u0101t savu tirgus dominanci pieaugo\u0161\u0101s konkurences un piepras\u012bjuma p\u0113c pieejam\u0101kiem aptauko\u0161an\u0101s \u0101rst\u0113\u0161anas l\u012bdzek\u013ciem apst\u0101k\u013cos. Pirmajos devi\u0146os 2025. gada m\u0113ne\u0161os d\u0101\u0146u uz\u0146\u0113mums demonstr\u0113ja iespaid\u012bgu 15% p\u0101rdo\u0161anas pieaugumu un 10% darb\u012bbas pe\u013c\u0146as pieaugumu. Tom\u0113r t\u0101 prognozes p\u0101rskat\u012btas, samazinot prognoz\u0113to p\u0101rdo\u0161anas pieaugumu l\u012bdz 8-11% un darb\u012bbas pe\u013c\u0146u l\u012bdz 4-7%, paredzot l\u0113n\u0101ku izaugsmi GLP-1 klases medikamentiem diab\u0113ta un aptauko\u0161an\u0101s \u0101rst\u0113\u0161an\u0101.<\/p>\n
Vispasaules piepras\u012bjums p\u0113c pretsvaru medikamentiem ir strauji pieaudzis, jo jauni l\u012bdzek\u013ci, piem\u0113ram, Ozempic un Wegovy, g\u016bst popularit\u0101ti cilv\u0113ku vid\u016b, kuri mekl\u0113 ide\u0101lu risin\u0101jumu vesel\u012bg\u0101kai \u0137erme\u0146a formai. Tom\u0113r \u0161is tirgus, ko l\u012bdz \u0161im domin\u0113jis Novo Nordisk ar saviem produktiem, saskaras ar arvien sp\u0113c\u012bg\u0101ku konkurenci no t\u0101diem gigantiem k\u0101 Eli Lilly un Pfizer, kas pied\u0101v\u0101 savus inovat\u012bvus pretaptauko\u0161an\u0101s medikamentus.<\/p>\n","protected":false},"excerpt":{"rendered":"Tirgi atviegloti: Novo Nordisk atsauc savu pied\u0101v\u0101jumu Metsera ieg\u0101dei Glob\u0101lie kapit\u0101la tirgi uz\u0146\u0113ma zi\u0146as par Pfizer pan\u0101kumiem c\u012b\u0146\u0101…\n","protected":false},"author":2,"featured_media":46490,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[12949,77,76,1293,35,39,38,36,37,34,40,1291,12948,1290],"class_list":{"0":"post-46489","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-bizness","8":"tag-aptaukosanas-zales","9":"tag-bizness","10":"tag-business","11":"tag-farmacijas-tirgus","12":"tag-latvia","13":"tag-latvian","14":"tag-latviesu","15":"tag-latviesu-valoda","16":"tag-latviesuvaloda","17":"tag-latvija","18":"tag-lv","19":"tag-metsera","20":"tag-novo-nordisk","21":"tag-pfizer"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lv\/115532963703530258","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/46489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/comments?post=46489"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/46489\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media\/46490"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media?parent=46489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/categories?post=46489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/tags?post=46489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}